Pfizer beats estimates and keeps 2026 outlook after growth in newer drugs

Pfizer reported firstquarter results that exceeded Wall Street expectations and reaffirmed its fullyear 2026 outlook. The drugmaker said growth in newer and recently acquired products helped offset weaker sales in its Covidrelated business. The company posted adjusted earnings of 75 cents per share on revenue of $14.45 billion, both above analyst estimates. Revenue rose 5% from a year earlier, while net income fell slightly to $2.69 billion. Pfizer said higher sales from drugs such as Eliquis, Padcev and its RSV vaccine helped balance declines in its Covid vaccine and Paxlovid. The company maintained its forecast for adjusted profit of $2.80 to $3.00 per share and revenue of $59.5 billion to $62.5 billion for 2026.